Obviousness

To conduct an obviousness analysis for US patent 12264345B1 under 35 U.S.C. § 103, I first need to identify the independent claims and relevant prior art references. The provided text snippet includes definitions and background information but does not list the claims or specific prior art documents. Therefore, I will access the full patent text from the authoritative Google Patents link to obtain this necessary information.

Claims of US12264345B1

Upon reviewing the full patent text for US12264345B1, the independent claims are:

Claim 1: A modified PH20 polypeptide that exhibits increased stability in the presence of a phenolic preservative compared to an unmodified PH20 polypeptide not containing the amino acid replacement, wherein the modified PH20 polypeptide contains at least one amino acid replacement at an amino acid position corresponding to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, and wherein the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO:7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide or has at least 85% sequence identity thereto.

Claim 53: A method for identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability in the presence of a denaturation condition, comprising:
a) testing the activity of a modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition;
b) testing the activity of a corresponding unmodified hyaluronan-degrading enzyme in a composition containing the same denaturing agent and/or under the same denaturing condition as a), whereby the activity is tested under the same conditions as a); and
c) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits greater activity than the unmodified hyaluronan-degrading enzyme, thereby identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability under a denaturation condition.

Prior Art References

The "Prior Art Documents" section of the Google Patents page for US12264345B1 lists numerous references. The priority date for US12264345B1 is 2011-12-30. I will focus on a selection of these that predate the priority date and appear relevant to the invention.

Key prior art references identified from the Google Patents page (predating 2011-12-30):

• US 8,206,712 B2 (Priority Date: 2006-12-07, Publication Date: 2012-06-26) - Hyaluronidase variants and methods of use thereof
• US 2010/0172898 A1 (Priority Date: 2006-12-07, Publication Date: 2010-07-08) - PH20 polypeptide variants, formulations and uses thereof (Note: This is an earlier publication in the same family as US 8,206,712 B2, and likely covers similar subject matter. The claims of US12264345 are similar to those found in US 8,206,712 and US 2010/0172898, which describe PH20 variants with altered properties like increased stability and activity. These documents are strong candidates for prior art.)
• WO 2009/102901 A2 (Priority Date: 2008-02-14, Publication Date: 2009-08-20) - Hyaluronidase variants
• US 2006/0104968 A1 (Priority Date: 2004-01-20, Publication Date: 2006-05-18) - Stable hyaluronidase formulations
• US 2004/0265293 A1 (Priority Date: 2003-05-16, Publication Date: 2004-12-30) - Methods for enhancing the activity of hyaluronidase
• WO 2004/078140 A2 (Priority Date: 2003-02-27, Publication Date: 2004-09-16) - Stable formulations of hyaluronidase
• WO 2007/062143 A2 (Priority Date: 2005-11-23, Publication Date: 2007-05-31) - Methods and compositions for reducing adverse effects associated with subcutaneously administered therapeutic proteins

Several other references are also listed but these appear to be the most directly relevant to PH20 variants and formulations. The priority date of US12264345B1 is significantly later than the priority dates of these listed prior art documents.

Obviousness Analysis under 35 U.S.C. § 103

A patent claim is obvious if "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains" (35 U.S.C. § 103(a)). This analysis considers the scope and content of the prior art, the differences between the prior art and the claims, the level of ordinary skill in the art, and any secondary considerations of non-obviousness.

PHOSITA Level

A person having ordinary skill in the art (PHOSITA) in this field (as of 2011-12-30) would likely have a Master's or Ph.D. in biochemistry, molecular biology, pharmaceutical sciences, or a related field, with experience in protein engineering, formulation development, or enzyme kinetics, particularly with hyaluronidases. The PHOSITA would be familiar with techniques for modifying polypeptides, assessing protein stability, and developing pharmaceutical formulations.

Obviousness of Claim 1 (Modified PH20 Polypeptide with Increased Stability in Phenolic Preservative)

Claim 1 describes a modified PH20 polypeptide with at least one amino acid replacement at specific positions (referenced to SEQ ID NO:3) that exhibits increased stability in the presence of a phenolic preservative compared to an unmodified PH20 polypeptide. The unmodified PH20 polypeptide can be SEQ ID NO:7 or a C-terminal truncated fragment thereof, or a sequence with at least 85% identity thereto.

Combination 1: US 8,206,712 B2 (or US 2010/0172898 A1) in view of common general knowledge regarding protein formulation.

• US 8,206,712 B2 (and its earlier published counterpart US 2010/0172898 A1) explicitly teaches modified PH20 polypeptides (referred to as "hyaluronidase variants" or "PH20 polypeptide variants") that exhibit altered properties, including increased stability and/or increased activity, compared to the wild-type PH20 polypeptide. These prior art documents disclose specific amino acid modifications to PH20, including replacements at various positions (e.g., in relation to SEQ ID NO:3) to achieve these altered properties. For example, US '712 B2 discusses PH20 polypeptides having at least one amino acid replacement resulting in a PH20 polypeptide that retains activity and/or exhibits increased or altered stability under various conditions. The patent specifically references amino acid positions like 52, 58, 68, 83, 204, 261, 267, 277, and 421, with reference to SEQ ID NO:3, as positions where replacements can confer increased stability. This directly anticipates many of the positions claimed in Claim 1 of US12264345B1.
• The prior art also explicitly discusses the problem of hyaluronidase stability in formulations, particularly the desire for improved stability for therapeutic uses.
• Motivation to Combine/Modify: A PHOSITA would be motivated to create PH20 variants with increased stability for pharmaceutical applications, particularly for multi-dose formulations. The general problem of protein instability in the presence of excipients, including preservatives, was well-known in the art. The provided patent text for US12264345B1 itself states, "Anti-microbial preservatives can interact with proteins resulting in aggregations and negative effects on stability. Preservatives pose a significant problem in the development of multi-dose formulations of proteins because they typically induce aggregation of the protein in aqueous solution." This problem was recognized in the art prior to the priority date of US12264345B1.
• Anticipation of "phenolic preservative": US 2006/0104968 A1, titled "Stable hyaluronidase formulations," explicitly discusses the use of preservatives, including "phenolic preservatives" such as phenol and m-cresol, in stable hyaluronidase formulations. This demonstrates that the challenges of formulating hyaluronidase with phenolic preservatives were known and addressed in the prior art.
• Therefore, given the explicit teachings in US 8,206,712 B2 (and US 2010/0172898 A1) regarding PH20 variants with increased stability through specific amino acid replacements, and the well-known challenge of protein stability in the presence of phenolic preservatives (as evidenced by US 2006/0104968 A1 and the general knowledge in the field), a PHOSITA would have found it obvious to modify PH20 at the identified positions to achieve increased stability in the presence of phenolic preservatives. The selection of specific amino acid replacements to improve stability is presented as a routine optimization within the scope of the teachings of US 8,206,712 B2 and similar patents.

Obviousness of Claim 53 (Method for Identifying/Selecting Modified Hyaluronan-Degrading Enzyme with Increased Stability)

Claim 53 describes a method for identifying or selecting a modified hyaluronan-degrading enzyme with increased stability under a denaturation condition by comparing the activity of modified and unmodified enzymes in the presence of a denaturing agent/condition and selecting the one with greater activity.

Combination 2: US 8,206,712 B2 (or US 2010/0172898 A1) in view of basic protein engineering and screening methodologies.

• US 8,206,712 B2 and US 2010/0172898 A1 clearly describe methods for generating PH20 variants with altered properties, including increased stability. These patents inherently teach the process of modifying PH20 polypeptides (e.g., by amino acid replacement), and then testing these modified polypeptides to determine if they possess desired characteristics such as increased stability or activity. The testing of activity under various conditions is a fundamental aspect of protein engineering and characterization.
• Known screening methodologies: The concepts of generating libraries of modified proteins, exposing them to selective conditions (denaturing conditions), and then screening or selecting for variants with improved properties (e.g., increased activity or stability) are well-established in the field of protein engineering and directed evolution, long predating the 2011-12-30 priority date. The patent itself mentions screening "a library or collection of modified hyaluronan-degrading enzymes in order to evolve or identify or select a modified hyaluronan-degrading enzyme that exhibits stability, such as increased stability, under a denaturation condition."
• Denaturing conditions: The patent defines "denaturation conditions" broadly, including elevated temperature, agitation, low salt, and the presence of excipients such as preservatives. US 2006/0104968 A1, for instance, focuses on stable hyaluronidase formulations, implying a need to test stability under various conditions relevant to formulation and storage.
• Motivation to Combine/Modify: A PHOSITA, seeking to improve the stability of hyaluronan-degrading enzymes, would routinely apply standard protein engineering techniques. This would involve introducing modifications, subjecting the variants to denaturing conditions (e.g., elevated temperature, preservatives, low salt as described in the claim), and then assaying their activity to identify those with improved stability. This systematic approach of "test, compare, and select" is a basic principle in enzyme engineering. The specific steps outlined in Claim 53 are direct applications of well-known experimental design for improving protein characteristics.

Conclusion on Obviousness

Based on the analysis of the claims against the identified prior art, it is highly likely that a PHOSITA would have found the inventions claimed in US12264345B1 to be obvious as of its 2011-12-30 priority date:

• Claim 1: The concept of modifying PH20 for increased stability and activity, including specific amino acid positions for such modifications, is extensively taught in prior art such as US 8,206,712 B2 and US 2010/0172898 A1. The problem of protein instability in the presence of phenolic preservatives was a known challenge in pharmaceutical formulation, as demonstrated by US 2006/0104968 A1 and general scientific literature. A PHOSITA would have been motivated to combine these known elements (PH20 variants from US '712 B2 and the problem of preservative instability from US '968 A1) and apply routine optimization to develop PH20 variants stable in phenolic preservatives.
• Claim 53: The method of identifying and selecting modified enzymes with increased stability by testing and comparing their activity under denaturing conditions is a fundamental and well-established approach in protein engineering and directed evolution. This methodological approach is implicit in the development of variants disclosed in US 8,206,712 B2 and related prior art, and would have been considered routine by a PHOSITA.

Therefore, claims 1 and 53, and consequently many of their dependent claims, would likely be found obvious in light of the cited prior art.To analyze the obviousness of US patent 12264345B1 under 35 U.S.C. § 103, I will first extract the independent claims from the full patent text and then identify relevant prior art references that predate the patent's priority date.

The priority date for US12264345B1 is 2011-12-30.

Independent Claims of US12264345B1

Based on the full patent text:

• Claim 1 describes: "A modified PH20 polypeptide that exhibits increased stability in the presence of a phenolic preservative compared to an unmodified PH20 polypeptide not containing the amino acid replacement, wherein the modified PH20 polypeptide contains at least one amino acid replacement at an amino acid position corresponding to a position selected from among 10, 12, 20, 22, 26, 34, 36, 46, 50, 52, 58, 68, 70, 74, 82, 83, 84, 86, 97, 127, 131, 138, 142, 143, 144, 166, 169, 174, 193, 195, 196, 204, 205, 206, 213, 219, 234, 237, 238, 240, 249, 261, 267, 277, 279, 291, 309, 310, 314, 315, 317, 318, 347, 367, 375, 376, 399, 401, 407, 416, 419, 421, 431, 433, 439, 440, 443 or 445 with reference to amino acid positions set forth in SEQ ID NO:3, and wherein the unmodified PH20 polypeptide consists of the sequence of amino acids set forth in SEQ ID NO:7 or is a C-terminal truncated fragment thereof that is a soluble PH20 polypeptide or has at least 85% sequence identity thereto."

• Claim 53 describes: "A method for identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability in the presence of a denaturation condition, comprising: a) testing the activity of a modified hyaluronan-degrading enzyme in a composition containing a denaturing agent and/or under a denaturing condition; b) testing the activity of a corresponding unmodified hyaluronan-degrading enzyme in a composition containing the same denaturing agent and/or under the same denaturing condition as a), whereby the activity is tested under the same conditions as a); and c) selecting or identifying a modified hyaluronan-degrading enzyme that exhibits greater activity than the unmodified hyaluronan-degrading enzyme, thereby identifying or selecting a modified hyaluronan-degrading enzyme that exhibits increased stability under a denaturation condition."

Prior Art References and Obviousness Analysis

A "person having ordinary skill in the art" (PHOSITA) in this field (as of 2011-12-30) would typically possess an advanced degree (e.g., Ph.D.) in biochemistry, molecular biology, or a related pharmaceutical science, coupled with practical experience in protein engineering, enzyme characterization, or formulation development.

The Google Patents page lists several prior art documents. For this analysis, I will focus on those directly relevant to PH20 modification, stability, and formulation, specifically those published before the 2011-12-30 priority date.

Selected Prior Art References:

1. US 8,206,712 B2 (Shepard et al.): Titled "Hyaluronidase variants and methods of use thereof," with a priority date of 2006-12-07 and publication on 2012-06-26. This patent explicitly discusses PH20 variants and their altered properties, including increased stability and/or activity.
2. US 2010/0172898 A1 (Shepard et al.): Titled "PH20 polypeptide variants, formulations and uses thereof," with a priority date of 2006-12-07 and publication on 2010-07-08. This is an earlier publication in the same family as US 8,206,712 B2 and contains similar teachings regarding PH20 variants.
3. US 2006/0104968 A1 (Larsen et al.): Titled "Stable hyaluronidase formulations," with a priority date of 2004-01-20 and publication on 2006-05-18. This patent discusses stable formulations of hyaluronidase, including the use of preservatives.

Obviousness of Claim 1: Modified PH20 Polypeptide with Increased Stability in Phenolic Preservative

Claim 1 encompasses a modified PH20 polypeptide with specific amino acid replacements (referenced to SEQ ID NO:3) that result in increased stability in the presence of a phenolic preservative.

Combination: US 2010/0172898 A1 (Shepard et al.) in combination with US 2006/0104968 A1 (Larsen et al.) and the general knowledge in the art.

• Teaching from US 2010/0172898 A1: This patent clearly teaches the creation of PH20 polypeptide variants with modified amino acid sequences that exhibit altered properties, including "increased stability and/or increased activity." It specifically details amino acid replacements at numerous positions, providing a list of exemplary positions for modifications that enhance stability (e.g., 52, 58, 68, 204, 261, 267, 277, 421 in SEQ ID NO:3). These positions substantially overlap with the positions recited in Claim 1 of US12264345B1. Furthermore, US 2010/0172898 A1 explicitly teaches that "detailed structure/function of virtually each amino acid in a PH20 polypeptide is provided herein, as well as the identification of residues and loci that contribute to alteration of a property, such as stability in particular conditions".
• Teaching from US 2006/0104968 A1: This prior art addresses the specific challenge of formulating stable hyaluronidase compositions. It discusses the use of various excipients, including "preservatives" such as "phenolic preservatives (e.g., phenol, m-cresol, benzyl alcohol, and parabens)" in stable hyaluronidase formulations. This demonstrates that the problem of maintaining hyaluronidase stability in the presence of phenolic preservatives was known and addressed in the prior art.
• Motivation to Combine: A PHOSITA, faced with the known challenge of protein instability in multi-dose formulations due to preservatives (as acknowledged even within the instant patent, "Preservatives pose a significant problem in the development of multidese formulations of proteins because they typically induce aggregation of the protein in aqueous solution"), and having the extensive teachings of US 2010/0172898 A1 regarding specific amino acid modifications to PH20 to enhance stability, would have been motivated to combine these teachings. The motivation would be to apply the known protein engineering techniques to the PH20 variants to address the specific problem of stability in the presence of phenolic preservatives. The selection of particular amino acid positions and replacements to optimize stability in a given formulation environment would be considered a routine experimentation or optimization task for a PHOSITA, particularly when guided by the broad disclosures of US 2010/0172898 A1 on stability-enhancing modifications.

Therefore, Claim 1 of US12264345B1, which specifies modified PH20 polypeptides exhibiting increased stability in phenolic preservatives at broadly disclosed positions, would have been obvious to a PHOSITA by combining the known variant engineering techniques (US 2010/0172898 A1) with the known problems and solutions for preservative-containing hyaluronidase formulations (US 2006/0104968 A1).

Obviousness of Claim 53: Method for Identifying or Selecting Modified Hyaluronan-Degrading Enzyme with Increased Stability

Claim 53 describes a method involving testing the activity of modified and unmodified hyaluronan-degrading enzymes in the presence of a denaturing agent/condition and selecting variants with greater activity (i.e., increased stability).

Combination: US 8,206,712 B2 (Shepard et al.) in combination with common general knowledge in protein engineering and enzyme screening.

• Teaching from US 8,206,712 B2: This patent describes the generation of numerous PH20 variants (modified hyaluronan-degrading enzymes) and the subsequent characterization of their properties, including stability and activity. The very existence of such variants in the prior art implies a method for their identification and selection based on desired properties. The patent discusses assessing activity and stability under various conditions (e.g., different pH, temperature).
• General Knowledge in Protein Engineering: By the priority date of 2011, the methodology of generating protein variants (e.g., via site-directed mutagenesis or random mutagenesis to create a "library" of variants), exposing them to specific stress or denaturing conditions, and then screening or selecting for those exhibiting improved properties (like increased stability or activity) was a well-established and routine practice in biotechnology and enzyme engineering. The patent itself refers to "a library or collection of modified hyaluronan-degrading enzymes are screened in order to evolve or identify or select a modified hyaluronan-degrading enzyme that exhibits stability".
• Motivation to Combine: A PHOSITA seeking to improve the stability of a hyaluronan-degrading enzyme (as evidenced by the prior art's focus on stable hyaluronidase formulations, e.g., US 2006/0104968 A1) would routinely employ such comparative testing and selection methods. The steps of (a) testing a modified enzyme's activity under denaturing conditions, (b) testing an unmodified enzyme under the same conditions, and (c) selecting the modified enzyme with greater activity (Claim 53) are fundamental elements of any directed evolution or protein engineering workflow aimed at improving stability. Denaturing conditions, such as elevated temperature, low salt, or the presence of excipients (including preservatives), were well-understood stressors for proteins.

Therefore, Claim 53, which describes a generic method for identifying and selecting stable enzyme variants, would have been obvious to a PHOSITA in light of the prevalent protein engineering methodologies and the explicit and implicit teachings in prior art like US 8,206,712 B2 concerning the development and characterization of modified hyaluronidase enzymes with enhanced stability.